FiercePharma  Sep 14  Comment 
A month ago it appeared like Takeda might not get enough takers to move forward with its sweeping $2.3 billion offer to settle thousands of claims over the cancer risks of diabetes drug Actos. But over the weekend, the Japanese drugmaker said it...
GenEng News  Sep 10  Comment 
Takeda Pharmaceutical will partner with Gencia to co-develop its new class of small molecule drugs as drug candidates for hematological and inflammatory diseases, in a collaboration that could generate more than $500 million for Gencia, the...
FierceBiotech  Sep 10  Comment 
Japanese pharma giant Takeda is promising as much as $500 million to a previously under-wraps biotech company with some early-stage drugs that could provide a more tolerable alternative to steroid treatments.
FiercePharma  Aug 24  Comment 
With approvals in the U.S and Europe expected soon, it looked like Takeda would have time to get its new multiple myeloma treatment into the market before patents fell off of blockbuster Velcade in 2022. But CEO Christophe Weber may need to plot a...
FierceBiotech  Aug 21  Comment 
Takeda's top oncology prospect is moving toward approval in the European Union, as continental regulators have accepted the company's application and promised a shortened review period for the blood cancer treatment.
Benzinga  Aug 21  Comment 
Takeda Pharmaceutical Company Limited (OTC: TKPYY) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for ixazomib, an investigational oral proteasome inhibitor for the...
FiercePharma  Aug 14  Comment 
Takeda's new CEO, Christophe Weber, thought the Japanese drugmaker had freed itself of the drag from thousands of lawsuits tied to cancer risks from its diabetes drug Actos with a $2.37 billion settlement offer made in April. But despite an...
FiercePharma  Aug 7  Comment 
Takeda's not walking out on its partnership with Orexigen--something it threatened to do after the drugmaker leaked some early data on its obesity med, resulting in a cancelled trial. But it is making it pay for its mistakes.


No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki